Empowering People to be Ambassadors of their Own Health Since 1997.


Weekly News

Weekly news updates are currently posted on the Internet site and sent out via e-blast to provide up-to-date information on what has been covered in the news regarding hepatitis C in the previous week.  Topics include all stories related to hepatitis C  as well as personal stories and events.

HCV News                                                                                                                                                   

Week Ending 11/30/2015 

More deadly than HIV: Hepatitis C, a silent killer

‘Navin Vij was delivered by C-section on June 22, 1983. At 27 weeks, he was a micro-preemie, staying in the intensive care unit for a couple months. Eventually, he was released and grew into a healthy kid. Throughout his childhood, his mom would repeat a phrase to him, sometimes in Hindi but always with a warm smile, that stayed with him — everything happens for a reason. And the challenge in good and bad is to figure out why.’

Hepatitis C screening of prison inmates would benefit wider community, be cost-effective

The benefits of screening prison inmates for infection with the hepatitis C virus (HCV) and treating those who test positive for the infection would extend far beyond the prison population, according to projections made by investigators from Massachusetts General Hospital (MGH) and the University of Pittsburgh Graduate School of Public Health. In a report published in Annals of Internal Medicine, the research team describes how their simulation found that a prison-based screening and treatment program could reduce HCV transmission in the general community and would be highly cost effective over the long run.’

The Medicines Patent Pool Signs Licence with Bristol-Myers Squibb to Increase Access to Hepatitis C Medicine daclatasvir

‘The Medicines Patent Pool (MPP) today announced its first licence for a hepatitis C medicine, signing an agreement with Bristol-Myers Squibb for daclatasvir, a novel direct-acting antiviral that is proven to help cure multiple genotypes of the HCV virus.  The royalty-free licence will enable generic manufacture of daclatasvir for sale in 112 low- and middle-income countries (LMICs), 76 of which are World Bank classified middle-income nations.  Nearly two-thirds of all patients living with hepatitis C in the LMICs reside in the territory covered by this agreement.’

Expensive new Hep C drugs may be cost-effective even for early disease

‘Treating hepatitis C with expensive new medicines at the earliest signs of liver damage improves patients’ health and is also cost-effective, a new computer simulation suggests. “Going into this, I expected to find it did make sense to wait until there was a limited amount of liver disease, but what we found to our surprise is that it makes sense to start treatment at the earliest change in the liver,” said senior author Dr. James Kahn, of the University of California, San Francisco.’

Health plan guide now available for people living with HIV, hepatitis C, hepatitis B and those considering PrEP

‘Five leading California HIV organizations—Access Support Network, AIDS Project Los Angeles, Los Angeles LGBT Center, Project Inform, and San Francisco AIDS Foundation—have released an updated guide for people living with HIV, hepatitis C (HCV), hepatitis B (HBV), and individuals considering pre-exposure prophylaxis (PrEP) on choosing a health insurance plan through Covered California. The guide contains two parts.’

The True Hepatitis C Prevalence in the United States: It’s Higher Than What’s Usually Reported

‘Hepatitis C, the most common blood-borne virus in the U.S. is now curable, and has been making headlines recently. With interesting presentations at the 2015 Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), new hep C drugs on the horizon, the strengthening of AASLD’s HCV Guidelines, and the forcible stand on hepatitis C treatment taken by the Centers for Medicare and Medicaid, I am giddy with hope. However, a critical article by Brian Edlin and colleagues in November’s Hepatology was a chilly reminder that we have a big problem on our hands.’

Hepatitis C cure may cost as low as Rs 67k

‘In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.’

Treating a little-known epidemic in America’s prisons could have a surprising benefit for society

‘The hepatitis C virus causes cirrhosis, is the leading cause of certain liver cancers, and is the most frequent reason people need liver transplants. Dealing with those costly, debilitating, and long-term illnesses takes a toll on the healthcare system.’

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)